argenx SE reported $1.72B in Sales Revenues for its fiscal quarter ending in September of 2026.





Sales Change Date
AstraZeneca USD 16.21B 830M Sep/2026
Genmab DKK 1.16B 259M Jun/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
GRIFOLS EUR 2.04B 170M Sep/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lakefront Biotherapeutics EUR 7.11M 5M Sep/2026
Qiagen NV USD 487.78M 24.66M Sep/2026
UCB EUR 4.25B 764M Dec/2025